Accessibility Menu
BioElectronics logo

BioElectronics(OTC) BIEL

Market Cap$7.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-100%
5 Year-91%
1 Year+50%
1 Month+20%
$0.00
-25%
-0.00Today
BioElectronics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-29
BioElectronics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-22
1 month+20%USD 0.002026-06-29
3 month-25%USD 0.002026-04-30
Year to date-25%USD 0.002025-12-31
1 year+50%USD 0.002025-07-29
3 year-25%USD 0.002023-07-28
5 year-91.18%USD 0.002021-07-30
Since inception-99.94%USD 0.472004-04-12

BioElectronics Financials at a Glance

Market Cap

$7.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$505.05K

Net Income (TTM)

-$977.05K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.89 (Low)

Price

$0.00

Volume

2,485,678

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Jul 10, 2024

BIEL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioElectronics

Bioelectronics Corporation is an innovative electroceutical company focused on developing wearable neuromodulation devices aimed at alleviating neurological diseases and improving quality of life. The company offers a range of products designed for pain management across various applications, including musculoskeletal and menstrual pain therapies.

Products and Services
  • ActiPatch: A therapy device for musculoskeletal pain relief
  • Allay: A wearable device targeting menstrual pain
  • Smart Insole: Designed for heel pain management
Growth Outlook
  • Recent quarterly revenue increased to $158,077, up from $55,369
  • Gross profit margin improved to 60.7% in Q1 2023
  • Expansion into veterinary markets with HealFast for pets
Financial Highlights
  • Trailing twelve months (TTM) revenue of $1,000,000, indicating growth potential
  • Net income for Q1 2023 was -$209,354, showing ongoing investment in R&D
  • Current ratio at 0.038, highlighting liquidity challenges
Bioelectronics Corporation operates in the medical specialties sector, providing innovative solutions for pain management through its unique electroceutical devices. The company has shown promising growth in recent quarters, particularly with a significant increase in revenue and an improved gross profit margin. The expansion into veterinary markets with products like HealFast indicates a strategic move to diversify revenue streams. However, the financial data also reveals challenges, such as a negative net income and low liquidity ratios, which potential investors should consider. Overall, Bioelectronics Corporation presents an intriguing opportunity in the healthcare sector, particularly for those interested in the evolving field of electroceuticals.
AI Generated • Jul 24, 2026

Industry

Healthcare Equipment and Supplies

CEO

Kelly A. Whelan

Headquarters

Frederick, MD 21704, US

BIEL Financials

Key Financial Metrics (TTM)

Gross Margin

84.87%

Operating Margin

15.91%

Net Income Margin

-104.28%

Return on Equity

3.01%

Return on Capital

N/A

Return on Assets

-374.04%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

24.71B

Volume

2.49M

Avg. Volume

12.75M

Financials (TTM)

Gross Profit

$301.18K

Operating Income

-$529.26K

EBITDA

-$474.38K

Operating Cash Flow

-$472.16K

Capital Expenditure

$0.00

Free Cash Flow

-$472.16K

Cash & ST Invst.

$6.87K

Total Debt

$14.23M

BioElectronics Performance Analysis

BioElectronics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 707,412-56.0%
20232023-12-31USD 714,7081.0%
20242024-12-31USD 496,032-30.6%
20252025-12-31USD 510,6232.9%
BioElectronics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-06-30-32.5%
Q32022-09-30-80.2%
Q42022-12-3115.0%
Q12023-03-31185.5%
BioElectronics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.00N/A
20232023-12-31USD 0.00N/A
20242024-12-31USD 0.00N/A
20252025-12-31USD 0.00N/A
BioElectronics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-06-30-1078.6%
Q32022-09-30-66.5%
Q42022-12-3133.3%
Q12023-03-317.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q1 2023YOY CHG

Revenue

$158.08K

-56.1%

Gross Profit

$95.97K

-65.9%

Gross Margin

60.71%

N/A

Market Cap

$7.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$823.50K

N/A

Employees

9

N/A

Net Income

-$209.35K

-1115.9%

EBITDA

-$97.77K

-211.0%

Quarterly Fundamentals

Name
Q1 2023YOY CHG

Total Cash

$6.87K

+2659.4%

Total Debt

$14.23M

+6.6%

Accounts Receivable

$71.55K

-75.9%

Inventory

$91.96K

+165.6%

Long Term Debt

$12.53M

+47.3%

Short Term Debt

$1.70M

-64.9%

Return on Assets

-3.74%

N/A

Return on Invested Capital

-2.28%

N/A

Free Cash Flow

-$64.03K

+9.1%

Operating Cash Flow

-$64.03K

+9.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BGXXBright Green Corporation
$0.04+5328.57%
AIMLFAI/ML Innovations Inc.
$0.03-6.78%
PHRRFPharmaTher Holdings Ltd.
$0.04-4.44%
ADMTADM Tronics Unlimited, Inc.
$0.04+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About BIEL

What is the current price of BioElectronics?

BioElectronics is trading at $0.00 per share.

What is the 52-week range for BioElectronics?

Over the past 52 weeks, BioElectronics has traded between $0.00 and $0.00.

How much debt does BioElectronics have?

As of the most recent reporting period, BioElectronics reported total debt of $16.29M.

How much cash does BioElectronics have on hand?

BioElectronics reported $3.51K in cash and cash equivalents in its most recent financial results.

What is BioElectronics’s dividend yield?

BioElectronics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.